Prostate cancer: Zoledronic acid as an adjuvant therapy is well-tolerated and improves BMD
RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patientsProstate Cancer Prostatic Dis. 2013 Dec;16(4):382-6. doi: 10.1038/pcan.2013.35. Epub 2013 Oct 1
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
109 patients with nonmetastatic prostate cancer, undergoing androgen deprivation therapy (ADT) in combination with radiotherapy (RT), were randomized to receive a 4-mg infusion of zoledronic acid every 6 months for 3 years, as well as vitamin D and calcium supplements, or supplements alone. The purpose of this study was to examine the safety and efficacy of zoledronic acid with respect to the inci...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE